PFNX News and Press, Pfenex Inc. From 08/11/20

Oxbridge Re Holdings (NASDAQ: OXBR ) +112%  on Q2 results . More news on: Oxbridge Re Holdings Limited, Pfenex Inc., Immutep Limited, Stocks on the move, , Read more ...

Ligand Pharmaceuticals (NASDAQ: LGND ) has agreed to acquire Pfenex (NYSEMKT: PFNX ) at $12/share, equivalent to $438M in equity value, representing a 57% premium to Pfenex’s last close price of $7.66 on August 10. More news on: Ligand Pharmaceuticals Incorporated, Pfenex Inc....

Expands Ligand’s industry-leading technology offerings by adding a proprietary protein expression technology platform Business expected to be earnings accretive in 2021 and to contribute substantial annual royalty revenue and cash flow going forward Ligand Pharmaceut...

Pfenex Inc. (PFNX) Q2 2020 Earnings Conference Call August 06, 2020 04:30 PM ET Company Participants Eef Schimmelpennink - President & Chief Executive Officer Conference Call Participants Greg Fraser - Truist Securities Andy Hsieh - William Blair Francois Brisebois - Op...

Pfenex (NYSEMKT: PFNX ) : Q2 GAAP EPS of -$0.30 misses by $0.02 . More news on: Pfenex Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Commercialization and launch of first royalty bearing products position company for next phase of growth Multiple U.S. health plans add Teriparatide Injection to their formulary upon its June 2020 launch as Pfenex and Alvogen continue to pursue therapeutic equivalence designation; Rec...

SAN DIEGO, July 20, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Thursday, August 6, 2020. Pfenex will host a conference call and webcast to discuss ...

Pfenex ( PFNX -4.4% ) said Theramex, the European commercialization partner for Pfenex and Adalvo, receives a positive opinion for PF708 from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. More news on: Pfenex Inc., Healthcare stocks news, ...

Positive Opinion from Committee for Medicinal Products for Human Use (CHMP) for Livogiva marks important first step toward marketing authorization Pfenex’s commercial partner Adalvo entered into commercialization agreement in Latin America for PF708 with a large, multin...

Pfenex’s commercialization partner Alvogen will lead launch and commercialization efforts in the United States The first FDA-approved teriparatide with Forteo® 1-3  as the reference drug SAN DIEGO, June 12, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American...